** Pfizer PFE.N said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, as the drugmaker expects to be an "earnings growth" story over the next three years
** Median PT of brokerages covering the stock is $28 - data compiled by LSEG
ENCOURAGING COMMENTARY
** BMO Capital Markets ("outperform", PT: "$30") says outperformance this quarter (particularly on the cost side) positions Pfizer well for the rest of the year, derisking the company's forecast amid a tumultuous economic backdrop
** Jefferies (PT:$32) says PFE reported an ok Q1, adding the company's oncology drugs will start to resonate with investors
** Leerink Partners ("market perform") says the company had encouraging comments on tariffs, dividend and M&A
** J.P.Morgan (PT:$30) believes stronger new launch performance and/or further progress on the drugs in development will be necessary to significantly change the current narrative on the stock, which the brokerage sees as more likely from 2026
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。